SEC Form 4 · accession 0001179110-15-007287
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Weber
Officer — Chief Operating Officer
Period of report
May 5, 2015
Accepted (ET)
May 7, 2015 · 5:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par valueF5 | May 5, 2015 | A | 11,250 | $0.00 | A | 138,335 | D | |
| Common Stock, $.01 par valueF6,F7 | May 6, 2015 | S | 605 | $72.3424 | D | 137,730 | D | |
| Common Stock, $.01 par valueF6,F8 | May 6, 2015 | S | 800 | $74.2644 | D | 136,930 | D | |
| Common Stock, $.01 par valueF6,F9 | May 6, 2015 | S | 200 | $75.685 | D | 136,730 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $13.88 | holding | — | — | — | Apr 23, 2008 | Apr 23, 2017 | Common Stock | 30,000 | 100,000 | D |
| Stock Option (right to buy)F1,F2 | $13.80 | holding | — | — | — | May 23, 2009 | May 23, 2018 | Common Stock | 0 | 12,000 | D |
| Stock Option (right to buy)F3,F2 | $5.86 | holding | — | — | — | May 28, 2010 | May 28, 2019 | Common Stock | 0 | 51,000 | D |
| Stock Options (right to buy)F3,F2 | $5.86 | holding | — | — | — | Mar 31, 2010 | May 28, 2019 | Common Stock | 0 | 34,500 | D |
| Stock Option (right to buy)F3,F2 | $10.03 | holding | — | — | — | Jun 3, 2011 | Jun 3, 2020 | Common Stock | 0 | 50,000 | D |
| Stock Option (right to buy)F3,F2 | $22.44 | holding | — | — | — | May 22, 2013 | May 22, 2022 | Common Stock | 0 | 25,000 | D |
| Stock Option (Right to Buy)F3,F2 | $23.15 | holding | — | — | — | May 14, 2014 | May 14, 2023 | Common Stock | 0 | 23,000 | D |
| Stock Option (Right to Buy)F3,F4 | $21.55 | holding | — | — | — | May 14, 2015 | May 14, 2024 | Common Stock | 0 | 15,000 | D |
Explanation of responses
- F1Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- F2This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F3Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- F4These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F5Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 14, 2014. One third of these restricted stock units vested on May 5, 2015 (into an equal number of shares of common stock) upon the issuer's achievement of a certain performance milestone with the remaining vesting on the first and second anniversary of the date of the grant.
- F6Sale of common stock pursuant to reporting owner's 10b5-1 plan solely for payment of withholding tax liability associated with the vesting of performance-based awards of restricted stock units.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $72.0800 and $72.5900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $74.0300 and $74.7900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $75.4100 and $75.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.